Ash 2021 roundup
Evaluate Vantage's coverage of the Ash 2021 congress.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Why Breyanzi and Yescarta might refresh the parts Kymriah cannot reach
Novartis will not pursue Kymriah’s use in second-line lymphoma; but have Breyanzi and Yescarta proved enough to be filed in this setting?
Sanofi takes its time with fitusiran
Sanofi reckons it has a universal haemophilia therapy on its hands – but first it needs to test a lower dose.
Polivy underwhelms, but stays ahead of Car-T
The sun sets on Kymriah, but Novartis has a plan
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Bristol reveals its sons of Revlimid
Data in multiple myeloma and non-Hodgkin’s lymphoma make Bristol optimistic about follow-ons to Revlimid and Pomalyst.
Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Global Blood stems the bleeding
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Another factor fade, courtesy of Pfizer and Sangamo
Bluebird looks to revive Lentiglobin
Data in sickle cell disease look encouraging, but a filing is a way away.
Precision moves quickly to deal with allo disappointment
Like its two competitors Precision shows lack of durability with its allogeneic Car-T approach, but makes a quick move to next-gen assets.
Agios and Forma take different paths in sickle cell disease
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.
Ash 2021 late-breakers enable neat comparisons
Ash 2021 preview – as competition grows Autolus monetises
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
Ash 2021 preview – small increases and big falls
The early movers could point to a disappointing meeting.